Importantly, elevated serum levels of BAG3 were detected in patients with liver, pancreatic, and ovarian carcinomas compared to healthy controls, substantiating BAG3’s potential as a circulating biomarker reflective of tumor burden. Here, BAG3 is linked to ovarian carcinoma.